Literature DB >> 14499458

Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta.

Craig S Atwood1, Mark E Obrenovich, Tianbing Liu, Hsien Chan, George Perry, Mark A Smith, Ralph N Martins.   

Abstract

Although much maligned, the amyloid-beta (Abeta) protein has been shown to possess a number of trophic properties that emanate from the protein's ability to bind Cu, Fe and Zn. Abeta belongs to a group of proteins that capture redox metal ions (even under mildly acidotic conditions), thereby preventing them from participating in redox cycling with other ligands. The coordination of Cu appears to be crucial for Abeta's own antioxidant activity that has been demonstrated both in vitro as well as in the brain, cerebrospinal fluid and plasma. The chelation of Cu by Abeta would therefore be predicted to dampen oxidative stress in the mildly acidotic and oxidative environment that accompanies acute brain trauma and Alzheimer's disease (AD). Given that oxidative stress promotes Abeta generation, the formation of diffuse amyloid plaques is likely to be a compensatory response to remove reactive oxygen species. This review weighs up the evidence supporting both the trophic and toxic properties of Abeta, and while evidence for direct Abeta neurotoxicity in vivo is scarce, we postulate that the product of Abeta's antioxidant activity, hydrogen peroxide (H(2)O(2)), is likely to mediate toxicity as the levels of this oxidant rise with the accumulation of Abeta in the AD brain. We propose that metal ion chelators, antioxidants, antiinflammatories and amyloid-lowering drugs that target the reduction of H(2)O(2) and/or Abeta generation may be efficacious in decreasing neurotoxicity. However, given the antioxidant activity of Abeta, we suggest that the excessive removal of Abeta may prevent adequate chelation of metal ions and removal of O(2)(-z.ccirf;), leading to enhanced, rather than reduced, neuronal oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14499458     DOI: 10.1016/s0165-0173(03)00174-7

Source DB:  PubMed          Journal:  Brain Res Brain Res Rev


  69 in total

1.  PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease.

Authors:  Marwan N Sabbagh; Albert Agro; Joanne Bell; Paul S Aisen; Edward Schweizer; Douglas Galasko
Journal:  Alzheimer Dis Assoc Disord       Date:  2011 Jul-Sep       Impact factor: 2.703

Review 2.  The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease.

Authors:  Zi-Xuan Wang; Lan Tan; Jinyuan Liu; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

3.  Promotion of oxidative lipid membrane damage by amyloid beta proteins.

Authors:  Ian V J Murray; Michael E Sindoni; Paul H Axelsen
Journal:  Biochemistry       Date:  2005-09-20       Impact factor: 3.162

Review 4.  The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy.

Authors:  Alessandra Gaeta; Robert C Hider
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

5.  Phenotype-dependent susceptibility of cholinergic neuroblastoma cells to neurotoxic inputs.

Authors:  A Szutowicz; H Bielarczyk; S Gul; A Ronowska; T Pawełczyk; A Jankowska-Kulawy
Journal:  Metab Brain Dis       Date:  2006-05-25       Impact factor: 3.584

6.  Common key-signals in learning and neurodegeneration: focus on excito-amino acids, beta-amyloid peptides and alpha-synuclein.

Authors:  L F Agnati; G Leo; S Genedani; L Piron; A Rivera; D Guidolin; K Fuxe
Journal:  J Neural Transm (Vienna)       Date:  2008-11-19       Impact factor: 3.575

Review 7.  Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim.

Authors:  Orly Weinreb; Silvia Mandel; Orit Bar-Am; Tamar Amit
Journal:  J Neural Transm (Vienna)       Date:  2011-03-01       Impact factor: 3.575

8.  Capturing a reactive state of amyloid aggregates: NMR-based characterization of copper-bound Alzheimer disease amyloid β-fibrils in a redox cycle.

Authors:  Sudhakar Parthasarathy; Brian Yoo; Dan McElheny; William Tay; Yoshitaka Ishii
Journal:  J Biol Chem       Date:  2014-02-12       Impact factor: 5.157

9.  Brain ischemia and ischemic blood-brain barrier as etiological factors in sporadic Alzheimer's disease.

Authors:  Ryszard Pluta; Marzena U Amek
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

10.  Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options.

Authors:  Bayani Uttara; Ajay V Singh; Paolo Zamboni; R T Mahajan
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.